Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

4-AcO-DMT

From Wikipedia, the free encyclopedia
Psychedelic drug

Pharmaceutical compound
4-AcO-DMT
Clinical data
Other names4-Acetoxy-N,N-dimethyltryptamine; 4-Acetoxy-DMT; 4-AcO-DMT;O-Acetylpsilocin; Psilacetin; Psiloacetin; Synthetic shrooms
Routes of
administration
Oral,intravenous,intranasal,rectal
Drug classSerotonergic psychedelic;Hallucinogen;Serotonin receptor agonist
ATC code
  • None
Legal status
Legal status
Identifiers
  • 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl acetate
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC14H18N2O2
Molar mass246.310 g·mol−1
3D model (JSmol)
Melting point172 to 173 °C (342 to 343 °F)
  • CC(=O)Oc2cccc1[nH]cc(CCN(C)C)c12
  • InChI=1S/C14H18N2O2/c1-10(17)18-13-6-4-5-12-14(13)11(9-15-12)7-8-16(2)3/h4-6,9,15H,7-8H2,1-3H3 checkY
  • Key:RTLRUOSYLFOFHV-UHFFFAOYSA-N checkY
  (verify)

4-Acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or4-acetoxy-DMT), also known asO-acetylpsilocin orpsilacetin, is apsychedelicdrug of thetryptamine family related topsilocybin andpsilocin.[1][2][3][4] It is asyntheticderivative of psilocin (4-HO-DMT) in which thehydroxyl group has beenacetylated, and is theanalogue of psilocybin (4-PO-DMT) in which thephosphateester has been replaced with an acetateester.[1][2][3] The drug is aprodrug of psilocin and isorally active similarly to psilocybin.[1][2][5]

As a prodrug of psilocin, 4-AcO-DMT acts as anon-selectiveserotonin receptor agonist, including of theserotonin5-HT2A receptor.[1][6] Thehallucinogenic effects of psilocin are thought to be mediated by activation of this receptor, although otherreceptors also contribute to its effects.[7][8][1] 4-AcO-DMT's effects are reported to be similar to those of psilocybin andpsilocybin mushrooms.[2][5][1] However, it has been said to have reducedside effects such asnausea andbody load that can be caused by ingestion of whole psilocybin mushrooms.[2][5][1] It is also said to have a fasteronset and shorterduration than psilocybin.[5] The drug is not expected to differ from psilocybin or psilocin in terms ofsafety.[1] 4-AcO-DMT is modestly lesspotent by weight than psilocybin in animals when they are given atequimolar doses.[2]

4-AcO-DMT was first described in apatent byAlbert Hofmann in 1963 and itschemical synthesis was improved byDavid E. Nichols and colleagues in 1999.[2][6][3] It was suggested by Nichols as a more economical and accessible alternative to psilocybin for use inscientific research, as the synthesis of psilocybin is more challenging and as psilocybin is acontrolled substance.[2][6][3] 4-AcO-DMT was first detected as adesigner drug inEurope in 2009.[6] It became increasingly prevalent as arecreational drug in the 2010s and has been the most commonly used novel tryptamine.[2][5] In the 2020s, 4-AcO-DMT became widely encountered in the form ofmushroom edibles in theUnited States as an alternative to psilocybin.[9][10][11][12] Relatedly, it has sometimes been referred to as "synthetic shrooms".[4] Mushrooms edibles may contain 4-AcO-DMT,Amanita muscaria mushroom constituents, or non-mushroom drugs such asbath salts, and have been linked topoisonings and deaths.[13][4][12][9]

4-AcO-DMT is not scheduled under United States law or any international drug schedules, including theUnited Nations 1971Convention on Psychotropic Substances, making it a potentially more accessible alternative to psilocybin for research.[2] It can be imported and possessed for research in the United States if labeled “not for human consumption,” but using itin vivo is illegal and violates theFederal Analogue Act.[1]

Use and effects

[edit]
See also:Psilocin § Uses,Psilocin § Effects,Psilocybin § Uses, andPsilocybin § Effects

Claims of subjective differences in effects between the acetylated and non-acetylated forms of psilocin vary: some users report that 4-AcO-DMT lasts slightly longer, whilst others report that it lasts for a considerably shorter time.[14][better source needed] Many users report lessbody load and nausea compared with psilocin.[5] Some users find that the visual effects produced by 4-AcO-DMT more closely resemble those produced byDMT than those produced by psilocin or psilocybin. Despite the preceding reports however, there have been no controlled clinical studies to distinguish the subjective effects of psilacetin, psilocin, and psilocybin.

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]
See also:Psilocybin § Pharmacology, andPsilocin § Pharmacology

Pharmacodynamics

[edit]
Psilocin at molecular targets
TargetAffinity (Ki, nM)
5-HT1A49–567 (Ki)
130–>3,160 (EC50Tooltip half-maximal effective concentration)
0.7%–96% (EmaxTooltip maximal efficacy)
5-HT1B31–305
5-HT1D19–36
5-HT1E44–52
5-HT1FND
5-HT2A6.0–340 (Ki)
2.4–3,836 (EC50)
16–98% (
Emax)
5-HT2B4.6–410 (Ki)
2.4–>20,000 (EC50)
1.4–84% (
Emax)
5-HT2C10–141 (Ki)
9.1–30 (EC50)
86–95% (
Emax)
5-HT3>10,000
5-HT4ND
5-HT5A70–84
5-HT657–72
5-HT73.5–72
α1Aα1B>10,000
α2A1,379–2,044
α2B1,271–1,894
α2C4,404
β1β2>10,000
D120–>14,000
D23,700–>10,000
D3101–8,900
D4>10,000
D5>10,000
H11,600–>10,000
H2H4>10,000
M1M5>10,000
σ1>10,000
σ2>10,000
I2792
TAAR11,400 (Ki) (rat)
17,000 (Ki) (mouse)
920–2,700 (EC50) (rodent)
>30,000 (
EC50) (human)
SERTTooltip Serotonin transporter3,650–>10,000 (Ki)
662–3,900 (IC50Tooltip half-maximal inhibitory concentration)
561 (EC50)
54% (
Emax)
NETTooltip Norepinephrine transporter13,000 (Ki)
14,000 (IC50)
>10,000 (
EC50)
DATTooltip Dopamine transporter6,000–>30,000 (Ki)
>100,000 (IC50)
>10,000 (
EC50)
Notes: The smaller the value, the more avidly psilocin interacts with the site.Sources:[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]

4-AcO-DMT is aprodrug ofpsilocin (4-HO-DMT).[2] As a prodrug of psilocin, 4-AcO-DMT acts as anon-selectiveagonist ofserotonin receptors, including of theserotonin5-HT2A receptor.[1] Thepsychedelic effects of 4-AcO-DMT are mediated specifically by activation of the serotonin 5-HT2A receptor.[1]

Similarly topsilocybin, psilocin, and otherserotonergic psychedelics, 4-AcO-DMT produces thehead-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2][6][4][34] In addition, like psilocybin and other psychedelics, 4-AcO-DMT fully substitutes for the psychedelicDOM in rodentdrug discrimination tests.[35] 4-AcO-DMT produces effects such ashypolocomotion andhypothermia in rodents as with psilocin as well.[2]

Pharmacokinetics

[edit]

There are noclinical studies of thepharmacokinetics of 4-AcO-DMT as of 2024.[2] However, thepharmacokinetics of 4-AcO-DMT have been studied in rodents.[2] The drug was confirmed to act as aprodrug ofpsilocin similarly topsilocybin (4-PO-DMT).[2] However, given byintraperitoneal injection atequimolar doses, 4-AcO-DMT showed only 70% of therelative bioavailability ortotal exposure of psilocybin.[2] Hence, 4-AcO-DMT results in modestly lower psilocin levels than psilocybin even when the drugs are given at equivalent doses with adjustment for differences inmolecular weight.[2] Along similar lines, the psilocin concentrations with 4-AcO-DMT 15 minutes after administration were 75 to 90% of those of an equimolar dose of psilocybin.[2] Theelimination half-life of psilocin was approximately 30 minutes and did not differ between 4-AcO-DMT and psilocybin.[2] Psilocinester prodrugs like 4-AcO-DMT arecleaved into psilocin byesteraseenzymes.[36]

A 2025in-vitro study examined the stability and metabolism of several psilocin ester prodrugs, including 4-AcO-DMT.[37] The results showed that 4-AcO-DMT was rapidly broken down into psilocin by esterase enzymes, with over 99.9% of the prodrug converted within 5 minutes under conditions mimicking the human body (i.e., in human plasma).[37] These findings support the idea that 4-AcO-DMT is quickly and efficiently converted into psilocin before it enters the bloodstream, and that the prodrug itself likely contributes little to the overall pharmacological effect.[37]

Chemistry

[edit]
4-AcO-DMT shown in powder form.

4-AcO-DMT can be obtained byacetylation of psilocin underalkaline or stronglyacidic conditions. It is, therefore, asynthetic compound. 4-AcO-DMT is more resistant than psilocin to oxidation under basic conditions due to its acetoxy group. It is not as difficult as psilocybin to synthesize.

Given enough time in unfavorable conditions, 4-AcO-DMT can sometimes turn into a degraded form which is brown in color and can even progress into a brown/black tar-like substance. Researchers hypothesize this is a polymerization reaction and is said to have no effect on thepotency of the substance. PreliminaryGCMS analysis of the closely relatedhomologue4-AcO-DET suggests that this degraded form of 4-AcO-DMT consists mainly of the hydroxy form of the parent molecule.[38]

4-AcO-DMT is a lower homologue of4-AcO-MET, 4-AcO-DET,4-AcO-MiPT and4-AcO-DiPT. Otheranalogues of 4-AcO-DMT include4-AcO-DPT,4-MeO-DMT, and4-PrO-DMT (O-propionylpsilocin).

History

[edit]

4-AcO-DMT and several other esters of psilocin werepatented on January 16, 1963, bySandoz Ltd viaAlbert Hofmann and Franz Troxler.[39][40] Despite this, psilacetin remains a psychedelic compound with a limited history of use. It is theorized to be aprodrug of psilocin, as is psilocybin, which occurs naturally in many species of psychedelic mushrooms. This is because the aromatic acetyl moiety on the 4th position of the indole ring system is subject to deacetylation in acidic conditions such as those found in the stomach.[41] Psilacetin isO-acetylated psilocin, whereas psilocybin isO-phosphorylated.

Society and culture

[edit]

Legal status

[edit]

International

[edit]

4-AcO-DMT is not scheduled under any international drug schedules, including theUnited Nations 1971Convention on Psychotropic Substances, making it a potentially more accessible alternative to psilocybin for research.[42]

Australia

[edit]

4-AcO-DMT can be considered an analog ofpsilocin making it a Schedule 9 prohibited substance in Australia under thePoisons Standard (October 2015).[43] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[43]

Czech Republic

[edit]

4-AcO-DMT is prohibited in Czech republic except strictly limited research and therapeutical purposes.[44]

Germany

[edit]

4-AcO-DMT is banned according to theBtMG since it's an ester of psilocin.[45]

Israel

[edit]

4-AcO-DMT is technically illegal in Israel as of being a derivative of DMT.[citation needed]

Italy

[edit]

4-AcO-DMT is illegal in Italy as it is anester of a prohibited substance.[citation needed]

Sweden

[edit]

The Riksdag added 4-AcO-DMT toNarcotic Drugs Punishments Act underswedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of January 25, 2017, published byMedical Products Agency (MPA) in regulationHSLF-FS 2017:1 listed as "4-acetoxi-N,N-dimetyltryptamin".[46]

United Kingdom

[edit]

4-AcO-DMT, being an ester of psilocin, is aClass A drug in the UK under theMisuse of Drugs Act 1971.[47]

United States

[edit]

In the United States, psilacetin can be legally sold and possessed when labeled as “not for human consumption” and intended solely for research purposes.[1] However, its use in humans is prohibited under the Federal Analogue Act, as it is considered acontrolled substance analogue of psilocybin.[1] The Controlled Substance Analogue Enforcement Act of 1986 (of which the Federal Analogue Act is part) criminalized the creation ofdesigner drugs.[48] As such, it is illegal in the United States.[49]

4-AcO-DMT is listed (often under 4-Aco-DMT) as a controlled substance at the state level in multiple states in the USA, includingAlabama which has made it a schedule I at the state level on March 18, 2014, along with several other tryptamine analogs.[50]

See also

[edit]

References

[edit]
  1. ^abcdefghijklmGeiger HA, Wurst MG, Daniels RN (October 2018)."DARK Classics in Chemical Neuroscience: Psilocybin"(PDF).ACS Chem Neurosci.9 (10):2438–2447.doi:10.1021/acschemneuro.8b00186.PMID 29956917.A chemically modified psilocin precursor, known as psilacetin (20), O-acetylpsilocin, or 4-acetoxy-N,N-dimethyltryptamine, which replaces the phosphoryloxy group found on psilocybin with an acetoxy group, is also readily available. The substituted acetoxy group is believed to be metabolized in an equivalent manner to the phosphoryloxy group, both producing psilocin during first-pass metabolism.37 This simple modification skirts written laws in the United States when the product is clearly designated "not for human consumption," allowing pseudolegal import and possession for research purposes only; however, if it were to be used in vivo, the user would be in violation of the Federal Analogue Act.38 Although psilacetin has been hypothesized to act as an identical pharmacological substitute for psilocybin, many users report a small, yet significant, difference in the effects of each drug.39 Psilacetin is often described as having a faster onset of action without the anxiety and nausea associated with psilocybin-containing mushroom ingestion (which could be due to avoiding the ingestion of the significant amounts of chitin usually found in these mushrooms) and to have a shorter duration of action with a more peaceful experience throughout, leaving most users with a positive afterglow.37,39
  2. ^abcdefghijklmnopqrstJones NT, Wagner L, Hahn MC, Scarlett CO, Wenthur CJ (2024)."In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin".Front Psychiatry.14 1303365.doi:10.3389/fpsyt.2023.1303365.PMC 10804612.PMID 38264637.
  3. ^abcdNichols D, Fescas S (1999)."Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin"(PDF).Synthesis.1999 (6):935–938.CiteSeerX 10.1.1.690.8071.doi:10.1055/s-1999-3490.S2CID 32044725.Archived(PDF) from the original on 17 February 2012. Retrieved17 January 2012.
  4. ^abcdWright W (24 June 2024)."4-AcO-DMT Is the Most Accessible (and Mysterious) Drug on the Market Right Now".DoubleBlind Mag. Retrieved2 February 2025.
  5. ^abcdefPalamar JJ, Acosta P (January 2020)."A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines".Human Psychopharmacology.35 (1) e2719.doi:10.1002/hup.2719.PMC 6995261.PMID 31909513.4-AcO-DMT (4-acetoxyN,N-dimethyltryptamine, O-acetylpsilocin, or psilacetin) was the most prevalent tryptamine reported with 30.8% of the sample reporting use and two thirds (66.7%) of tryptamine users reporting use. 4-AcO-DMT—often pronounced as "4-akko-DMT"—was reported by most users as producing similar effects as psilocybin mushrooms with less nausea. One participant referred to this compound as "silly pills," which is a play on the name psilocybin. This particular compound was often preferred over natural mushrooms due to the lack of adverse side effects such as nausea, which the natural mushroom tends to produce. Thus, participants often suggested that 4-AcODMT allows one to achieve the same high as psilocybin without adverse physical effects such as nausea and heavy body load. One participant did complain of dry mouth and mentioned that although 4-AcO-DMT feels similar to psilocybin, he said it lacks the "organic" feel produced by psilocybin. [...] Of the most common tryptamines used by this sample, the majority of these compounds were first discovered or first synthesized as early as the 1930s (e.g., 5-MeO-DMT), 1950s (e.g., 4-AcO-DMT), or in the 1970s (e.g., 4-HO-MET and 5-MeO-DIPT). [...] 4-AcO-DMT was the most commonly used tryptamine by participants, and this compound also appears to be among the most prevalent novel tryptamines in recent years (Palamar & Le, 2019; PalmaConesa et al., 2017). [...] 4-AcO-DMT is often described as having a faster onset of action than psilocybin with a high of shorter duration, and as many of our participants noted, use allows them to avoid the nausea commonly associated mushroom ingestion (Geiger et al., 2018). Despite 4-AcO-DMT being among the most prevalent tryptamines, and having been discovered in the 1950s, little academic research has focused on recreational use of this compound.
  6. ^abcdeKlein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, et al. (April 2021)."Investigation of the Structure-Activity Relationships of Psilocybin Analogues".ACS Pharmacol Transl Sci.4 (2):533–542.doi:10.1021/acsptsci.0c00176.PMC 8033608.PMID 33860183.
  7. ^Halberstadt AL (January 2015)."Recent advances in the neuropsychopharmacology of serotonergic hallucinogens".Behav Brain Res.277:99–120.doi:10.1016/j.bbr.2014.07.016.PMC 4642895.PMID 25036425.
  8. ^Kwan AC, Olson DE, Preller KH, Roth BL (November 2022)."The neural basis of psychedelic action".Nat Neurosci.25 (11):1407–1419.doi:10.1038/s41593-022-01177-4.PMC 9641582.PMID 36280799.
  9. ^abBlakinger K, Sheets C (9 August 2024)."Magic mushroom chocolates are having a moment. But do they even contain mushrooms?".Los Angeles Times. Retrieved1 February 2025.
  10. ^Ovalle D (4 July 2024)."Psychedelic mushroom edibles promise health benefits. Be wary, experts say".Washington Post. Archived fromthe original on 4 July 2024. Retrieved1 February 2025.
  11. ^Syal A (18 July 2024)."Mushroom edibles are rising in popularity. It's hard to say what's in them".NBC News. Retrieved1 February 2025.
  12. ^abDucharme J (4 October 2024)."Are Mushroom Edibles Safe and Legal?".TIME. Retrieved1 February 2025.
  13. ^Mole B (5 July 2024)."What we know about microdosing candy illnesses as death investigation underway".Ars Technica. Retrieved1 February 2025.
  14. ^"4-AcO-DMT (also 4-acetoxy-N,N-dimethyltryptamine) : Erowid Exp: Main Index".www.erowid.org.Archived from the original on 2010-07-28.
  15. ^Liu T."BindingDB BDBM50081701 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol::4-hydroxy-N,N-dimethyltryptamine::CHEMBL65547::N,N-dimethyl-4-hydroxytryptamine::Psilocin::US11427604, Compound (I-45)::US11453689, Compound Psilocin::US11591353, Compound I-45::US11597738, Example 3::US11642336, Compound Psilocin::US20240051978, Compound Psilocin".BindingDB. Retrieved5 September 2024.
  16. ^Liu T."BindingDB BDBM50171269 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate::4-phosphoryloxy-N,N-dimethyltryptamine::CHEMBL194378::Indocybin::O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine::Psilocybine::US11597738, Example 4::psilocin phosphate ester::psilocybin".BindingDB. Retrieved5 September 2024.
  17. ^"PDSP Database".UNC (in Zulu). Retrieved2024-09-05.
  18. ^"PDSP Database".UNC (in Zulu). Retrieved2024-09-05.
  19. ^Holze F, Singh N, Liechti ME, D'Souza DC (May 2024)."Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile".Biol Psychiatry Cogn Neurosci Neuroimaging.9 (5):472–489.doi:10.1016/j.bpsc.2024.01.007.PMID 38301886.
  20. ^Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, et al. (August 2023)."Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy"(PDF).CNS Spectr.28 (4):416–426.doi:10.1017/S1092852922000888.PMID 35811423.
  21. ^Tylš F, Páleníček T, Horáček J (March 2014)."Psilocybin - summary of knowledge and new perspectives".Eur Neuropsychopharmacol.24 (3):342–356.doi:10.1016/j.euroneuro.2013.12.006.PMID 24444771.
  22. ^Wojtas A, Gołembiowska K (December 2023)."Molecular and Medical Aspects of Psychedelics".Int J Mol Sci.25 (1): 241.doi:10.3390/ijms25010241.PMC 10778977.PMID 38203411.
  23. ^Rickli A, Moning OD, Hoener MC, Liechti ME (August 2016)."Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens"(PDF).Eur Neuropsychopharmacol.26 (8):1327–1337.doi:10.1016/j.euroneuro.2016.05.001.PMID 27216487.
  24. ^Ray TS (February 2010)."Psychedelics and the human receptorome".PLOS ONE.5 (2) e9019.Bibcode:2010PLoSO...5.9019R.doi:10.1371/journal.pone.0009019.PMC 2814854.PMID 20126400.
  25. ^Plazas E, Faraone N (February 2023)."Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents".Biomedicines.11 (2): 461.doi:10.3390/biomedicines11020461.PMC 9953455.PMID 36830997.
  26. ^US 11440879, Andrew Carry Kruegel, "Methods of treating mood disorders", published 10 February 2022, assigned to Gilgamesh Pharmaceuticals, Inc. 
  27. ^Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE (April 2012)."Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters".The Journal of Pharmacology and Experimental Therapeutics.341 (1):251–262.doi:10.1124/jpet.111.188946.PMC 3364510.PMID 22271821.
  28. ^Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014)."Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes".Psychopharmacology (Berl).231 (21):4135–4144.doi:10.1007/s00213-014-3557-7.PMC 4194234.PMID 24800892.
  29. ^Marek GJ, Makai-Bölöni S, Umbricht D, Christian EP, Winters J, Dvorak D, et al. (October 2025). "A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer".J Psychopharmacol 2698811251378512.doi:10.1177/02698811251378512.PMID 41099491.
  30. ^Wsół A (December 2023)."Cardiovascular safety of psychedelic medicine: current status and future directions".Pharmacol Rep.75 (6):1362–1380.doi:10.1007/s43440-023-00539-4.PMC 10661823.PMID 37874530.
  31. ^Chen X, Li J, Yu L, Maule F, Chang L, Gallant JA, et al. (October 2023)."A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines".J Biol Chem.299 (10) 105231.doi:10.1016/j.jbc.2023.105231.PMC 10570959.PMID 37690691.
  32. ^Chen X, Li J, Yu L, Dhananjaya D, Maule F, Cook S, et al. (10 March 2023),Bioproduction platform using a novel cane toad (Rhinella marina) N-methyltransferase for psychedelic-inspired drug discovery(PDF),doi:10.21203/rs.3.rs-2667175/v1, retrieved18 March 2025
  33. ^Gainetdinov RR, Hoener MC, Berry MD (July 2018)."Trace Amines and Their Receptors".Pharmacol Rev.70 (3):549–620.doi:10.1124/pr.117.015305.PMID 29941461.
  34. ^Halberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior".Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 159–199.doi:10.1007/7854_2016_466.ISBN 978-3-662-55878-2.PMC 5787039.PMID 28224459.
  35. ^Gatch MB, Hoch A, Carbonaro TM (April 2021)."Discriminative Stimulus Effects of Substituted Tryptamines in Rats".ACS Pharmacol Transl Sci.4 (2):467–471.doi:10.1021/acsptsci.0c00173.PMC 8033599.PMID 33860176.
  36. ^Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, et al. (January 2024)."Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders".J Med Chem.67 (2):1024–1043.doi:10.1021/acs.jmedchem.3c01225.PMC 10823477.PMID 37983270.
  37. ^abcEklund J, Bremberg U, Larsson J, Torkelsson E, Wennerberg J, Zandelin S, et al. (March 2025)."Synthesis and In Vitro Profiling of Psilocin Derivatives: Improved Stability and Synthetic Properties".J Med Chem.68 (7):7153–7165.doi:10.1021/acs.jmedchem.4c02612.PMC 11997985.PMID 40108981.
  38. ^"Erowid 4-Acetoxy-DET Vaults : 4-Acetoxy-DET / Ethacetin Degradation".erowid.org. 4 July 2003. Retrieved10 September 2023.
  39. ^US patent 3075992, Hofmann A, Troxler F, "Esters of indoles", assigned to Sandoz Ltd. 
  40. ^US 3075992 
  41. ^Staněk J, Černá MJ (January 1963). "Acidic deacetylation of sugar acetates".Tetrahedron Letters.4 (1):35–7.doi:10.1016/S0040-4039(01)90572-6.
  42. ^Jones NT, Wagner L, Hahn MC, Scarlett CO, Wenthur CJ (2024)."In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin".Front Psychiatry.14 1303365.doi:10.3389/fpsyt.2023.1303365.PMC 10804612.PMID 38264637.
  43. ^ab"Poisons Standard October 2015".Federal Register of Legislation. Australian Government. 30 September 2015.Archived from the original on 2016-01-19. Retrieved2016-01-06.
  44. ^"Government regulation of the list of the addictive substances".Federal Register of Legislation. Czech Government.
  45. ^"Anlage I BtMG".Einzelnorm (in German). Retrieved2024-11-21.
  46. ^"Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika" [Regulations on changes in the Swedish Medicines Agency's regulations (LVFS 2011:10) on lists of narcotics](PDF) (in Swedish).Archived(PDF) from the original on 2017-10-31. Retrieved2017-04-21.
  47. ^Misuse of Drugs Act 1971 (Schedule 2 Part I). 1971.
  48. ^"Controlled Substance Analogue Enforcement Act of 1986: The Compromising of Criminalization | Office of Justice Programs".www.ojp.gov. Retrieved2025-06-13.
  49. ^Johnson R (2024-09-11)."A Psychedelic Debacle: 4-AcO, Microdosing, Media Panics and the Risks of Prohibition".Rolling Stone. Retrieved2025-06-13.
  50. ^"Controlled Substances List"(PDF).Alabama State Board of Health. 22 February 2024. p. 50. Archived fromthe original(PDF) on 8 August 2024. Retrieved18 August 2024.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
TAAR1Tooltip Trace amine-associated receptor 1
Agonists
Endogenous
Exogenous
Antagonists
Inverse agonists
TAAR5Tooltip Trace amine-associated receptor 5
Agonists
Inverse agonists
Notes: (1) TAAR1 activity of ligands varies significantly between species. Some agents that are TAAR1 ligands in some species are not in other species. This navbox includes all TAAR1 ligands regardless of species. (2) See the individual pages for references, as well as theList of trace amines,TAAR, andTAAR1 pages.
See also:Receptor/signaling modulators
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=4-AcO-DMT&oldid=1323688105"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp